TY - JOUR
T1 - Prospective study of recovery from copperhead snake envenomation
T2 - An observational study
AU - Copperhead Snakebite Recovery Outcome Group
AU - Lavonas, Eric J.
AU - Gerardo, Charles J.
AU - Arcuri, Karen
AU - Daugherty, Claire A.
AU - Temu, Anna
AU - Anderson, Victoria E.
AU - Bartelson, Becki Bucher
AU - Coulter, Michael S.
AU - Gillman, Stephanie M.
AU - Goodman, Erin M.
AU - Khatri, Vaishali
AU - Lones, Jason E.
AU - Spradley, Elizabeth A.
AU - Sun, Jun
AU - Drake, Weiying G.
AU - Arnold, Thomas C.
AU - Hutchinson, Kimberley
AU - Lewis, Brandon J.
AU - Lewis, Debbie
AU - Amlin, Tina C.
AU - Morgan, David L.
AU - Dykes, Cathy
AU - Witham, William R.
AU - Bowers, Rebecca C.
AU - Short, Joann
AU - Cox, Robert D.
AU - Becker, Lea H.
AU - Charlton, Nathan P.
AU - Toschlog, Eric A.
AU - Watkins, Frank R.
AU - Rose, S. Rutherfoord
AU - Mullins, Michael E.
N1 - Funding Information:
The authors would like to thank the following individuals who also made major contributions to this study: John M. Atkins (project management), Michael Bade (outcome instrument selection), Danielle Bradbury (regulatory oversight), Thomas King (publications logistics), Margaret Ann McCormick (site coordination, training, and oversight), Shiva Noorchashm (investigator meeting logistics), Janet Rush (project oversight). In addition, this study was supported by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. Contents are the authors’ sole responsibility and do not necessarily represent official NIH views, nor those of the University of Colorado.
Funding Information:
This study was funded by BTG International, Inc, the manufacturer of FabAV. The coordinating center and each study site received research grant support for participation in this study. The Denver Health and Hospital Authority and the Duke University School of Medicine have received research support for other projects from BTG International, Inc. The Denver Health and Hospital Authority has research, call center, and consulting agreements with BTG and the manufacturers of other antivenom products. Ms. Arcuri, Ms. Daugherty, and Ms. Temu are employees or contract employees of BTG International, Inc. Drs. Arnold, Gerardo, and Rose have received compensation from BTG for other work. The other authors declare that they have no competing interests outside their employment relationships, as above.
Publisher Copyright:
© 2015 Lavonas et al.
PY - 2015/5/15
Y1 - 2015/5/15
N2 - Background: Although much is known about signs, symptoms, and management in the acute phase of crotaline snake envenomation, little is known about signs, symptoms, function, and quality of life during the recovery phase. The purpose of this observational pilot investigation is to evaluate the utility of several clinical outcome instruments in the setting of copperhead snakebite, and to characterize the clinical course of recovery. Methods: This is a multi-center prospective, open-label, observational study of patients envenomated by copperhead snakes. We administered the Disabilities of the Arm, Shoulder, and Hand (DASH), Lower Extremity Functional Scale (LEFS), Patient-Specific Functional Scale (PSFS), Work Productivity and Ability Impairment: Special Health Problem (WPAI: SHP), Patients' Global Impression of Change (PGIC), Patient's Global Assessment of Recovery (PGAR), and SF-36 instruments, obtained numeric pain rating scales, and measured grip strength, walking speed, and swelling prior to hospital discharge and 3, 7, 14, 21, and 28 days after envenomation. Results: 20 subjects were enrolled; none were lost to follow-up. Most (80%) had moderate severity swelling, and most (75%) received antivenom. Across the broad range of measures, abnormalities of pain, swelling, impairments of physical and role function, and quality of life persisted for 7-14 days in most subjects. Validated self-reported outcome measures, such as the DASH, LEFS, PSFS, PGIC, SF-36, and the daily activities impairment portion of the WPAI: SHP were more responsive than measurements of swelling or walking speed. Data quality issues limited the utility of the work impairment portion of the WPAI: SHP. Residual signs, symptoms, and impairment in some subjects lasted through the 28-day study period. The study design precluded any assessment of the effectiveness of antivenom. Conclusions: Signs, symptoms, impaired function, and decreased quality of life typically last 7 - 14 days after copperhead envenomation. Several tools appear responsive and useful in studying recovery from pit viper envenomation.
AB - Background: Although much is known about signs, symptoms, and management in the acute phase of crotaline snake envenomation, little is known about signs, symptoms, function, and quality of life during the recovery phase. The purpose of this observational pilot investigation is to evaluate the utility of several clinical outcome instruments in the setting of copperhead snakebite, and to characterize the clinical course of recovery. Methods: This is a multi-center prospective, open-label, observational study of patients envenomated by copperhead snakes. We administered the Disabilities of the Arm, Shoulder, and Hand (DASH), Lower Extremity Functional Scale (LEFS), Patient-Specific Functional Scale (PSFS), Work Productivity and Ability Impairment: Special Health Problem (WPAI: SHP), Patients' Global Impression of Change (PGIC), Patient's Global Assessment of Recovery (PGAR), and SF-36 instruments, obtained numeric pain rating scales, and measured grip strength, walking speed, and swelling prior to hospital discharge and 3, 7, 14, 21, and 28 days after envenomation. Results: 20 subjects were enrolled; none were lost to follow-up. Most (80%) had moderate severity swelling, and most (75%) received antivenom. Across the broad range of measures, abnormalities of pain, swelling, impairments of physical and role function, and quality of life persisted for 7-14 days in most subjects. Validated self-reported outcome measures, such as the DASH, LEFS, PSFS, PGIC, SF-36, and the daily activities impairment portion of the WPAI: SHP were more responsive than measurements of swelling or walking speed. Data quality issues limited the utility of the work impairment portion of the WPAI: SHP. Residual signs, symptoms, and impairment in some subjects lasted through the 28-day study period. The study design precluded any assessment of the effectiveness of antivenom. Conclusions: Signs, symptoms, impaired function, and decreased quality of life typically last 7 - 14 days after copperhead envenomation. Several tools appear responsive and useful in studying recovery from pit viper envenomation.
KW - Agkistrodon
KW - Antivenins
KW - Crotalid venoms
KW - Disability evaluation
KW - Lower extremity
KW - Quality of Life
KW - Recovery of function
KW - Snake bites
KW - Upper extremity
UR - http://www.scopus.com/inward/record.url?scp=84930211131&partnerID=8YFLogxK
U2 - 10.1186/s12873-015-0033-6
DO - 10.1186/s12873-015-0033-6
M3 - Article
C2 - 25975429
AN - SCOPUS:84930211131
SN - 1471-227X
VL - 15
JO - BMC Emergency Medicine
JF - BMC Emergency Medicine
IS - 1
M1 - 9
ER -